Roche has some good data using their drug Lucentis, on diabetic eye issues. It is a leading cause of blindness. It is a blockbuster drug. It addresses swelling or inflammation in the eye and leaky blood vessels. TB 4 is also believed to be an anti inflammatory in the eye...and RGRX was doing some early work in diabetic trial, but the population they were after was a far smaller indication, and had a very hard time signing pts. Not to say they can't try later. Who knows. Just that diabetic issues in the eye (inflammation) -and dry eye are both blockbuster categories, revenue wise.
I wish the physician sponsoerd phase 2 would hurry up and release results. It was a small study and started near end of 2010. It makes some sense that RGRX would not initiate a far larger phase 2...done by the top clinical eye firm, Ora Inc...until they see how the physician one did. If results are good, it will speed FDA okay for the trial, and it will significantly speed up patient sign up in Ora Inc's trial...docs will be eager to sign on.